Latest News and Press Releases

George Medicines files New Drug Application with FDA for novel low dose triple combination for treatment of hypertension following successful international Phase III development program ...

George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director London, UK 29 April 2024 – George Medicines, a late-stage, biopharmaceutical company addressing significant unmet...

George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2 All patients enrolled in active-controlled trial...

George Medicines provides single-pill triple combination candidate for hypertension to VERONICA-Nigeria trial Novel proprietary low-dose, single-pill triple combination, GMRx2, is in late-stage...

George Medicines advances triple combination candidate GMRx4 into Phase II clinical development for first-line treatment of type 2 diabetes GMRx4 is the second candidate to be prioritised in...

Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill 500 UK patients to be treated as part of global trial Investigational single-pill combination offers potential to...

Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill 500 UK patients to be treated as part of global trial Investigational single-pill combination offers potential to...

George Medicines appoints Dr Charmaine Gittleson as Non-Executive Director London, UK, 12 July 2021 – George Medicines, a late-stage drug development company focused on providing innovative and...

George Medicines appoints Dr Charmaine Gittleson as Non-Executive Director London, UK, 12 July 2021 – George Medicines, a late-stage drug development company focused on providing innovative and...

George Medicines initiates two Phase III trials of triple combination candidate to treat hypertension Novel proprietary triple low-dose combination pill has been shown to outperform traditional blood...